Biopharmaceutical company Tryptamine Therapeutics (ASX: TYP) has successfully and safely completed first subject dosing in its Phase 1b study into an obese subject population.
The open-label study at CMAX Clinical Research in Adelaide using TRP-8803 to determine if there are any differences in pharmacokinetic parameters compared to previous studied non-obese patients. The study will add three obese participants to the Company’s existing Phase 1b study protocol.
Tryp advises that the first participant was provided TRP-8803 on Thursday, 21 November for approximately 140 minutes and safely progressed through the treatment. The participant was discharged shortly after dosing follow-up was completed.
Two additional study applicants will receive dosing over the coming weeks. Results are anticipated to support TRP- 8803’s dosing within obese study participants and to provide valuable and cost-effective data to optimise dose selection for the company’s Phase 2 clinical program using TRP-8803 in specific indications. Interim results from the obese subject population are anticipated this year.
“We are very excited to have commenced this trial focused on an obese subject population. The initiative is very capital efficient and will provide the company with valuable data to further refine TRP-8803 dosing rates across a broader cross section of the population, while also building on our comprehensive dataset,” CEO, Jason Carroll, said.
“The first patient dosing follows exceptional and positive results from an initial three patient cohorts, which have determined TRP-8803’s safety, optimal dose and infusion rates and highlighted TRP-8803’s ability to achieve improved health outcomes at scale.
“This dataset will be used to inform the xompany’s phase 2 trial planning, which will explore the application of TRP- 8803 across specific indications. The Board and management are assessing a number of opportunities in relation to Phase 2 trials for TRP-8803 and look forward to providing further updates as developments materialise.”
